Hemogenyx Pharmaceuticals PLC (PNK:HOPHF) to undergo a reverse stock split, exchanging 1 share for every 400 shares.
The company has restructured its capital by subdividing and reclassifying its shares, aiming to streamline its share structure.
HOPHF is currently priced at $0.0031, with a market capitalization of approximately $19.9 million.
On Friday, December 13, 2024, PNK:HOPHF, traded on the PNK exchange, will undergo a reverse stock split. In this event, 1 share will be exchanged for every 400 shares. Hemogenyx Pharmaceuticals PLC, the company behind HOPHF, focuses on developing therapies for blood diseases. It is listed on the London Stock Exchange under the symbol HEMO.
Hemogenyx Pharmaceuticals recently announced the admission of new ordinary shares after resolutions were approved at its Extraordinary General Meeting on December 9, 2024. The company has restructured its capital by subdividing and reclassifying its 1.4 billion ordinary shares on a 1:2 basis. This resulted in each existing share being divided into one new ordinary share and one deferred share.
Following this, the new ordinary shares were consolidated on a 400:1 basis. This means every 400 new ordinary shares were combined into one new ordinary share valued at £0.01 each. This strategic move aims to streamline Hemogenyx Pharmaceuticals’ share structure, as highlighted by the company’s recent actions.
The stock symbol HOPHF is currently priced at $0.0031, with a daily low of $0.0031 and a high of $0.04. Over the past year, the stock has also seen a high of $0.04 and a low of $0.0031. The market capitalization of HOPHF stands at approximately $19.9 million, with a trading volume of 25,000 shares for the day.
